Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Experimental RNAi02:15

Experimental RNAi

8.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.0K
Types of RNA01:23

Types of RNA

73.3K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
73.3K
RNA Interference01:23

RNA Interference

28.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Team Approach: Diagnosis and Management of Pediatric Pelvic Ewing Sarcoma.

JBJS reviews·2026
Same author

Do Patients Who Undergo Conversion of Failed Osteoarticular Allografts to Megaprostheses Have Worse Outcomes Than Patients Treated With Primary Megaprostheses at Initial Resection?

Clinical orthopaedics and related research·2026
Same author

Inhibition of CDK9 sensitizes multidrug resistant ovarian cancer cells to paclitaxel.

Scientific reports·2026
Same author

Tyrosine-Peptide Analog Modulates Extracellular Vesicles miRNAs Cargo from Mesenchymal Stem/Stromal and Cancer Cells to Drive Immunoregeneration and Tumor Suppression.

Biomolecules·2026
Same author

The IlluminOss photodynamic bone stabilization system: novel technology with broad application in orthopaedic fracture fixation.

Expert review of medical devices·2026
Same author

Cervical spine chordomas: surgical outcome assessment in a multicenter cohort from the Primary Tumor Research and Outcomes Network.

Journal of neurosurgery. Spine·2026
Same journal

Retraction: Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.

Oncotarget·2026
Same journal

TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.

Oncotarget·2026
Same journal

Retraction: MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.

Oncotarget·2026
Same journal

Laryngeal leiomyosarcoma: A rare case report and literature review.

Oncotarget·2026
Same journal

Correction: Postsurgery fluids promote transition of cancer stem cell toendothelial and AKT/mTOR activity contributing to relapse of giant cell tumors of bone.

Oncotarget·2026
Same journal

DHHC3 interferes with antitumor immunity in melanoma cells.

Oncotarget·2026
See all related articles

Related Experiment Video

Updated: Feb 21, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.4K

Noncoding RNA in drug resistant sarcoma.

Xiaoyang Li1,2, Jacson K Shen2, Francis J Hornicek2

  • 1Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.

Oncotarget
|October 6, 2017
PubMed
Summary
This summary is machine-generated.

Drug resistance in sarcoma limits treatment success. This review explores how noncoding RNAs, like microRNAs and long noncoding RNAs, play a role in drug-resistant sarcoma and their future therapeutic potential.

Keywords:
drug resistancelong noncoding RNA (lncRNA)microRNA (miR)noncoding RNA (ncRNA)sarcoma

More Related Videos

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

2.4K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Experiment Videos

Last Updated: Feb 21, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.4K
Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

2.4K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Sarcomas are malignant tumors originating from mesenchymal cells.
  • Current sarcoma treatments face challenges due to drug resistance, leading to plateaued survival rates.
  • Traditional research focused on protein-coding genes, but noncoding RNAs are emerging as key players.

Purpose of the Study:

  • To review the current understanding of noncoding RNAs in drug-resistant sarcoma.
  • To highlight the characteristics of noncoding RNAs and their regulated genes in this context.
  • To explore the therapeutic potential of noncoding RNAs for overcoming sarcoma drug resistance.

Main Methods:

  • Literature review of existing research on noncoding RNAs and sarcoma.
  • Analysis of studies investigating the role of microRNAs and long noncoding RNAs in drug resistance.
  • Synthesis of information on gene regulation by noncoding RNAs in sarcoma.

Main Results:

  • Noncoding RNAs, including microRNAs and long noncoding RNAs, are implicated in the development of drug resistance in sarcoma.
  • These noncoding RNAs regulate various genes that contribute to chemoresistance.
  • Understanding these mechanisms opens new avenues for therapeutic intervention.

Conclusions:

  • Noncoding RNAs represent a promising area for developing novel strategies to combat drug resistance in sarcoma.
  • Targeting noncoding RNAs could potentially reverse or overcome resistance to existing chemotherapies.
  • Further research into noncoding RNA biology is crucial for advancing sarcoma treatment.